Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
- 1 July 2019
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 116, 207-215
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanomaOncoImmunology, 2017
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabClinical Cancer Research, 2016
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaJAMA, 2016
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi ResistanceCell, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibitionCancer, 2014
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsCancer, 2014
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010